New mouse models give a boost to the development of cancer immunotherapies

Thursday, June 2, 2016 - 13:11 in Health & Medicine

A new cancer treatment called CD40 inhibitor has yielded disappointing results when tested in clinical trials, failing to mobilize patients’ immune system against tumors the way it was expected to. But a recent study offers clues about how this experimental drug might be optimized to fulfill its potential. More »

Read the whole article on The Rockefeller University

More from The Rockefeller University

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net